US FDA accepts MS drug Lemtrada resubmission for review
US FDA accepts MS drug Lemtrada resubmission for review
The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA. Genzyme expects FDA action on the sBLA in the fourth quarter...... Read More - http://www.ms-uk.org/lemtrada
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1827 Views
-
Last post by frodo
-
- 0 Replies
- 1175 Views
-
Last post by NHE
-
- 0 Replies
- 1650 Views
-
Last post by frodo
-
- 0 Replies
- 1179 Views
-
Last post by frodo
-
- 1 Replies
- 1617 Views
-
Last post by frodo
-
- 0 Replies
- 1966 Views
-
Last post by NHE
-
- 0 Replies
- 2221 Views
-
Last post by NHE
-
- 0 Replies
- 1024 Views
-
Last post by frodo
-
- 1 Replies
- 1349 Views
-
Last post by NHE